Enlivex Therapeutics Ltd. financial data

Symbol
ENLV on Nasdaq
Location
37 Dereh Menachem Begin St., 15 Th Floor, Tel Aviv, Israel
Fiscal year end
December 31
Latest financial report
6-K - Q2 2025 - Aug 29, 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.7M shares +27.2%
Common Stock, Shares, Outstanding 23.9M shares +14.2%
Common Stock, Value, Issued 2.71M USD +13.5%
Weighted Average Number of Shares Outstanding, Basic 23.9M shares +22.1%
Weighted Average Number of Shares Outstanding, Diluted 23.9M shares +22.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.14M USD +7.1%
General and Administrative Expense 937K USD -5.07%
Operating Income (Loss) -3.08M USD -3.08%
Nonoperating Income (Expense) 1.21M USD
Net Income (Loss) Attributable to Parent -1.87M USD +39.7%
Earnings Per Share, Basic -0.08 USD/shares +50%
Earnings Per Share, Diluted -0.08 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.89M USD -49.5%
Marketable Securities, Current 6K USD -97.4%
Other Assets, Current 6.59M USD
Assets, Current 21.3M USD -25.4%
Property, Plant and Equipment, Net 490K USD -57.7%
Operating Lease, Right-of-Use Asset 433K USD -50.2%
Other Assets, Noncurrent 784K USD -38.6%
Assets 22.6M USD -29.2%
Accounts Payable, Current 303K USD
Employee-related Liabilities, Current 347K USD +10.5%
Accrued Liabilities, Current 2.79M USD
Liabilities, Current 3.33M USD +17.1%
Operating Lease, Liability, Noncurrent 216K USD -56.7%
Other Liabilities, Noncurrent 216K USD -56.7%
Liabilities 3.54M USD +6.11%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.1M USD 0%
Retained Earnings (Accumulated Deficit) -132M USD -11%
Stockholders' Equity Attributable to Parent 19.1M USD -33.3%
Liabilities and Equity 22.6M USD -29.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 45M shares 0%
Common Stock, Shares, Issued 23.9M shares +14.2%
Common Stock, Par or Stated Value Per Share 0.4 ILS/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.35M USD -43.6%
Deferred Tax Assets, Valuation Allowance 37.3M USD +10.6%
Deferred Tax Assets, Gross 37.3M USD +10.6%
Operating Lease, Liability 480K USD -42.5%
Depreciation 85K USD -46.9%
Lessee, Operating Lease, Liability, to be Paid 561K USD -40.6%
Property, Plant and Equipment, Gross 3.65M USD -12.6%
Operating Lease, Liability, Current 264K USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 147K USD -23.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 170K USD -52.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +29.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 81K USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 99K USD -15.4%
Deferred Tax Assets, Operating Loss Carryforwards 31.5M USD +17.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 88K USD -27.3%
Additional Paid in Capital 148M USD
Share-based Payment Arrangement, Expense 295K USD -24%